1. Home
  2. CBIO vs ARKO Comparison

CBIO vs ARKO Comparison

Compare CBIO & ARKO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Crescent Biopharma Inc.

CBIO

Crescent Biopharma Inc.

HOLD

Current Price

$13.14

Market Cap

553.9M

Sector

N/A

ML Signal

HOLD

Logo ARKO Corp.

ARKO

ARKO Corp.

HOLD

Current Price

$3.99

Market Cap

466.7M

Sector

Energy

ML Signal

HOLD

Company Overview

Basic Information
Metric
CBIO
ARKO
Founded
2003
1970
Country
United States
United States
Employees
N/A
N/A
Industry
Oil Refining/Marketing
Sector
Energy
Exchange
Nasdaq
Nasdaq
Market Cap
553.9M
466.7M
IPO Year
2013
2021

Fundamental Metrics

Financial Performance
Metric
CBIO
ARKO
Price
$13.14
$3.99
Analyst Decision
Strong Buy
Buy
Analyst Count
8
2
Target Price
★ $31.50
$8.50
AVG Volume (30 Days)
339.6K
★ 516.1K
Earning Date
11-05-2026
11-04-2026
Dividend Yield
N/A
★ 2.98%
EPS Growth
N/A
★ 15.38
EPS
N/A
★ N/A
Revenue
$18,500.00
★ $9,142,799,000.00
Revenue This Year
N/A
$22.11
Revenue Next Year
$177.36
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 23.26
52 Week Low
$8.72
$3.95
52 Week High
$27.41
$8.76

Technical Indicators

Market Signals
Indicator
CBIO
ARKO
Relative Strength Index (RSI) 41.82 35.59
Support Level $10.25 $3.98
Resistance Level $13.41 $4.30
Average True Range (ATR) 1.07 0.13
MACD 0.02 0.02
Stochastic Oscillator 42.29 10.29

Price Performance

Historical Comparison
CBIO
ARKO

About CBIO Crescent Biopharma Inc.

Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.

About ARKO ARKO Corp.

ARKO Corp owns and operates convenience stores in the United States. Some of its regional store brands include Stop, Admiral, Apple Market, BreadBox, E-Z Mart, fas mart, Li'l Cricket, and Next Door Store. Its retail store offers hot food service, beverages, cigarettes & other tobacco products, candy, salty snacks, grocery, beer, and general merchandise. ARKO operates in four segments: Retail segment, Wholesale segment, fleet fueling segment, and GPM Petroleum segment. It derives the majority of its revenue from retail and wholesale distribution of fuel.

Share on Social Networks: